Ligand Pharmaceuticals Inc. (LGND)
| Market Cap | 2.01B |
| Revenue (ttm) | 208.41M |
| Net Income (ttm) | 39.25M |
| Shares Out | 16.44M |
| EPS (ttm) | 2.40 |
| PE Ratio | 49.50 |
| Forward PE | 19.92 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $118.96 |
| Previous Close | $123.45 |
| Change ($) | -4.49 |
| Change (%) | -3.64% |
| Day's Open | 123.34 |
| Day's Range | 118.26 - 125.54 |
| Day's Volume | 202,670 |
| 52-Week Range | 78.26 - 219.75 |
PALO ALTO, Calif., July 28, 2021 /PRNewswire/ -- Landing AI™ announced today a software licensing agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to incorporate LandingLens™ into Ligan...
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Partner Jazz Pharmaceuticals Launches RYLAZE (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
SAN DIEGO--(BUSINESS WIRE)---- $LGND--Ligand's Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND #earnings--Ligand to Report Second Quarter Financial Results on July 29, 2021
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors
Ligand (LGND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the...
SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, a biopharmaceutical company with a lead late clinical-stage program that represents a potential best-in-class therapy for presbyopia, today emerged from st...
Ligand (LGND) reported earnings 30 days ago. What's next for the stock?
NANJING, China and SAN DIEGO, June 2, 2021 /PRNewswire/ -- GenScript Biotech Corporation (HKG: 1548) along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) a...
Ligand (LGND) reports mixed first-quarter 2021 numbers with earnings beating estimates but revenues missing the same. Stock down.
Ligand (LGND) delivered earnings and revenue surprises of 34.29% and -15.61%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Ligand Pharmaceuticals (NASDAQ:LGND) fell 7% in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 58.43% over the past year to $1.41, whi...
SAN DIEGO--(BUSINESS WIRE)---- $LGND #earnings--Ligand Reports First Quarter 2021 Financial Results
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO--(BUSINESS WIRE)---- $LGND #earnings--Ligand to Report First Quarter Financial Results on May 3, 2021
The Reddit crowd wasn't the only reason short-sellers got burned betting against this pharmaceutical company.
On Friday, Ligand Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Ligand Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite Rating appeared...
Ligand Pharmaceuticals saw its IBD SmartSelect Composite Rating jump to 96 Wednesday, up from 93 the day before. The post Ligand Pharmaceuticals Gets A Composite Rating Upgrade appeared first on Investo...
Ligand (LGND) reported earnings 30 days ago. What's next for the stock?
LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, t...
Short interest rates can be used to predict the potential direction of an individual stock. When stocks have a high short interest rate that's a good indicator that investors believe their share prices ...
Retail investors have been on the hunt for the most shorted stocks to buy in the market this week. Share prices have reached record levels due to a rally of short squeezes.
Ligand (LGND) reports better-than-expected fourth-quarter 2020 numbers. The company raises outlook for 2021.
Shares of Ligand Pharmaceuticals (NASDAQ:LGND) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share rose 128.17% over the past year to $1.62, which beat the estimat...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2020 and provided an operating forecast and...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that their ongoing pivotal Phase 3 DUPLEX Study of sparse...
The GameStop effect will soon come to biopharma, an usually heavily-shorted sector. Here's a list of three of biopharma's more heavily-shorted stocks.
One Of The Most Shorted Names In Biotech: Ligand Pharmaceuticals
This week, Ligand Pharmaceuticals (NASDAQ:LGND) found itself at the center of unexpected attention. The second-most shorted company in the U.S. saw its shares rise from $120 to almost $200 as Reddit use...
New York, New York--(Newsfile Corp. - January 28, 2021) - Levi & Korsinsky, LLP, a national securities law firm that has recovered hundreds of millions of dollars for investors, announces that it has co...
An extreme level of herd mentality led by Reddit's 3 million member strong WallStreetBets forum has sparked an epic rally in the most shorted stocks in the market. The forum, members of which refer to e...
On Wednesday, Ligand Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 93 to 97. The post Top-Rated Stocks: Ligand Pharmaceuticals Sees Composite Rating Climb To 97 appeared f...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report fourth quarter 2020 financial results on February 3, 2021. Ligand's CEO John ...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported that the company will receive a $1.5 million milestone payment from Merck triggered by the U.S. Food and Dru...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today a collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline (GSK) to leverage...
Ligand has an interesting business plan that it is executing well. Ligand has three technologies that it calls out as important for its near- to mid-term success.
Ligand (LGND) reported earnings 30 days ago. What's next for the stock?
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces clinical and regulatory progress by multiple partners utilizing antibodies from its OmniAb® discovery platform. T...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administratio...
Ligand (LGND) reports lower-than-expected third-quarter 2020 earnings and revenues. Outlook for 2020 & 2021 also are below expectations.
Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q3 2020 Results - Earnings Call Transcript
Ligand (LGND) delivered earnings and revenue surprises of -1.89% and -8.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Ligand Pharmaceuticals (NASDAQ:LGND) were flat in pre-market trading after the company reported Q3 results.
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three- and nine-months ending September 30, 2020 and provided an operating forecas...
Higher Captisol sales to support availability of Gilead's COVID-19 treatment, remdisivir, is expected to have driven Ligand's (LGND) revenues in the third quarter.
Timothy P. Lynch's Stonepine Capital is a life science-focused hedge fund that seeks to utilize its industry experience to uncover undervalued and under-the-radar health companies. The fund takes a long...
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treat... [Read more...]
| Industry Biotechnology | IPO Date Nov 18, 1992 |
| CEO John Higgins | Employees 155 |
| Stock Exchange NASDAQ | Ticker Symbol LGND |
Analyst Forecasts
According to 8 analysts, the average rating for LGND stock is "Buy." The 12-month stock price forecast is 213.57, which is an increase of 79.53% from the latest price.